These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33441770)

  • 1. Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis.
    Kanbayashi Y; Sakaguchi K; Hongo F; Ishikawa T; Tabuchi Y; Ukimura O; Takayama K; Taguchi T
    Sci Rep; 2021 Jan; 11(1):978. PubMed ID: 33441770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
    Imatoh T; Sai K; Takeyama M; Hori K; Karayama M; Furuhashi K; Segawa K; Kimura M; Kawakami J; Saito Y
    J Clin Pharm Ther; 2019 Feb; 44(1):62-68. PubMed ID: 30144112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
    Huynh AL; Baker ST; Stewardson AJ; Johnson DF
    Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
    Body JJ; Bone HG; de Boer RH; Stopeck A; Van Poznak C; Damião R; Fizazi K; Henry DH; Ibrahim T; Lipton A; Saad F; Shore N; Takano T; Shaywitz AJ; Wang H; Bracco OL; Braun A; Kostenuik PJ
    Eur J Cancer; 2015 Sep; 51(13):1812-21. PubMed ID: 26093811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
    Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
    Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
    Body JJ; von Moos R; Niepel D; Tombal B
    BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the risk factors associated with hypocalcemia induced by denosumab.
    Okada N; Kawazoe K; Teraoka K; Kujime T; Abe M; Shinohara Y; Minakuchi K
    Biol Pharm Bull; 2013; 36(10):1622-6. PubMed ID: 23934346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocalcaemia after denosumab in older people following fracture.
    Chen J; Smerdely P
    Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.
    Kinoshita Y; Arai M; Ito N; Takashi Y; Makita N; Nangaku M; Shinoda Y; Fukumoto S
    Endocr J; 2016 May; 63(5):479-84. PubMed ID: 26860123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan.
    Imatoh T; Sai K; Takeyama M; Segawa K; Yamashita T; Nakashima N; Kataoka Y; Yokoi H; Hiramatsu T; Ohe K; Kimura M; Hori K; Kawakami J; Saito Y
    J Clin Pharm Ther; 2019 Oct; 44(5):788-795. PubMed ID: 31282013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis.
    Shrosbree JE; Elder GJ; Eisman JA; Center JR
    Intern Med J; 2018 Jun; 48(6):681-687. PubMed ID: 29363863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe hypocalcaemia following denosumab in a patient with cancer with vitamin D deficiency.
    Watthanasuntorn K; Abid H; Gnanajothy R
    BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases.
    Lechner B; DeAngelis C; Jamal N; Emmenegger U; Pulenzas N; Giotis A; Sheehan P; Tsao M; Bedard G; Chow E
    Support Care Cancer; 2014 Jul; 22(7):1765-71. PubMed ID: 24515277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
    Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
    J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and safety of denosumab in cancer patients.
    Manzaneque A; Chaguaceda C; Mensa M; Bastida C; Creus-Baró N
    Int J Clin Pharm; 2017 Jun; 39(3):522-526. PubMed ID: 28382583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?
    Tsvetov G; Amitai O; Shochat T; Shimon I; Akirov A; Diker-Cohen T
    Osteoporos Int; 2020 Apr; 31(4):655-665. PubMed ID: 31838550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D
    Ikegami K; Hashiguchi M; Kizaki H; Yasumuro O; Funakoshi R; Hori S
    J Clin Pharmacol; 2022 Sep; 62(9):1151-1159. PubMed ID: 35383950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.
    Blackley S; Anderson K; Berg J
    J R Coll Physicians Edinb; 2015; 45(2):133-5. PubMed ID: 26181529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
    Dave V; Chiang CY; Booth J; Mount PF
    Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.